Puma Biotech (PBYI) Tops Q1 EPS by 89c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Puma Biotechnology (PBYI) PT Lowered to $41 at Cowen
May 10, 2019 6:27 AM EDTCowen analyst Chris Shibutani lowered the price target on Puma Biotechnology (NASDAQ: PBYI) to $41.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "1Q19 Nerlynx sales widely missed expectations owing to a mix of factors, some familiar (greater discontinuations), others more discomforting... More
